Most With Intractable Meniere Disease Experience Symptom Relief
By Elana Gotkine HealthDay Reporter
THURSDAY, Dec. 5, 2024 -- Most patients with intractable Meniere disease (MD) experience symptom relief over time, according to a study published online Oct. 23 in Frontiers in Neurology.
F.R. Gerritsen, from Haga Hospital in The Hague, Netherlands, and colleagues described the evolution of vertigo attacks among patients with intractable MD in whom surgery was considered in a retrospective cohort study. Patients with definite unilateral MD and persisting vertigo attacks despite intratympanic steroid injection treatment were included in the study. All patients had been wait-listed for participation in a trial examining nonablative surgery; they were wait-listed between June 2016 and June 2021. To assess the evolution of the vertigo attacks, their data were collected in September 2022.
The analysis included 35 patients; 25 (71 percent) declined surgery. The researchers found that 21 of the 33 patients (64 percent) with complete information on vertigo attacks were free of vertigo attacks on data collection after a median disease duration of 5.3 years. The duration of disease was longer for patients who did versus those who did not undergo surgery.
"The current population was thought to suffer intractable disease, and yet most patients experienced relieve of symptoms in just over one year," the authors write. "Knowledge of the generally benign evolution of MD may be of value for patients and clinicians when weighing treatment options."
One author was employed by The Novo Nordisk Foundation Center for Stem Cell Medicine.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-06 06:00
Read more
- AHA: Obesity-Linked Ischemic Heart Disease Mortality Increasing in U.S.
- 5 Tips to a Healthy Tummy This Holiday Season
- Zepbound Bests Wegovy for Weight Loss in New Trial
- Illinois Study Finds Steep Rise in Serious Complications of Pregnancy
- Analysis Predicts Big Drop for U.S. in Global Health Rankings
- FDA Approves Rapiblyk (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions